Security National Financial Corporation reported a 38.6% drop in after-tax earnings for Q3 2026, falling to $6.17 million due to challenging mortgage market conditions and increased interest rates. The mortgage segment faced a $2.65 million loss driven by lower home sales and market volatility, while the insurance segment saw reduced profitability despite above-average investment yields. The cemetery and mortuary segment also experienced a profit decline due to market factors but showed growth in preneed cemetery sales. Despite earnings pressure, the company's stockholders' equity rose by 8.2% to $469 million, reflecting the positive impact of higher interest rates on insurance reserves. Management remains focused on its long-term strategy amid these mixed results.
Security National Financial Corporation's stockholders' equity rose by 8.2% to $469 million despite a 38.6% drop in after-tax earnings for Q3 2026. For readers following the Financials sector, here is Pluang's market snapshot as of Nov 10, 2026 00:52 WIB: out of 142 priced US Financials stocks, 129 rose and 12 fell today. Notable movers include PSEC at USD 1.54 (+9.22%), WULF at USD 12.20 (+7.30%), and BEN at USD 36.01 (+6.74%).
JIADE Ltd announced a registered direct offering of 6.67 million Class A shares at $0.18 each, raising approximately $1.2 million before fees. The funds will support its comprehensive education services for adult institutions in China, including soft...
Bureau Veritas disclosed its share and voting rights count as of October 31, 2026, reporting 453,899,720 shares outstanding. The company has a theoretical total of 579,429,535 voting rights, with 567,882,134 exercisable voting rights. This update ref...
Quadient S.A. has disclosed its monthly update on the total number of ordinary shares and voting rights as of October 30, 2026. The company reports 34,468,912 total shares and theoretical voting rights, with 34,091,172 net voting rights. This disclos...
Quadient S.A. disclosed its monthly update on shares and voting rights as of October 30, 2026. The company has a total of 34,468,912 ordinary shares and a net total of 34,091,172 voting rights. This information is relevant for shareholders and invest...
ADC Therapeutics reported a smaller adjusted loss per share of $0.16 in Q3 2026, beating the expected $0.21 loss, and revenue of $21.72 million, surpassing estimates of $18.7 million. The company’s main product, ZYNLONTA, continues to drive growth, w...
